Bavencio from Merck KGaA and Pfizer is available under the Early Access to Medicines Scheme (EAMS) as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest